Your browser is no longer supported. Please, upgrade your browser.
MGNX MacroGenics, Inc. daily Stock Chart
MGNX [NASD]
MacroGenics, Inc.
Index- P/E- EPS (ttm)-3.10 Insider Own2.30% Shs Outstand49.01M Perf Week3.46%
Market Cap1.47B Forward P/E- EPS next Y-1.87 Insider Trans-1.86% Shs Float45.55M Perf Month54.14%
Income-151.50M PEG- EPS next Q-0.92 Inst Own92.50% Short Float10.36% Perf Quarter429.86%
Sales68.20M P/S21.52 EPS this Y24.60% Inst Trans-1.43% Short Ratio1.42 Perf Half Y168.31%
Book/sh3.89 P/B7.85 EPS next Y47.20% ROA-46.20% Target Price29.36 Perf Year93.29%
Cash/sh3.55 P/C8.59 EPS next 5Y- ROE-62.40% 52W Range4.04 - 32.18 Perf YTD180.51%
Dividend- P/FCF- EPS past 5Y-17.70% ROI-76.80% 52W High-5.16% Beta2.82
Dividend %- Quick Ratio4.90 Sales past 5Y6.10% Gross Margin- 52W Low655.45% ATR1.85
Employees384 Current Ratio4.90 Sales Q/Q41.20% Oper. Margin- RSI (14)63.43 Volatility6.09% 7.61%
OptionableYes Debt/Eq0.00 EPS Q/Q7.60% Profit Margin- Rel Volume0.13 Prev Close30.68
ShortableYes LT Debt/Eq0.00 EarningsMay 05 AMC Payout- Avg Volume3.31M Price30.52
Recom1.80 SMA2012.40% SMA5031.91% SMA200140.85% Volume423,168 Change-0.52%
Jun-01-20Upgrade Guggenheim Neutral → Buy
May-26-20Reiterated H.C. Wainwright Buy $22 → $40
Mar-04-20Initiated Barclays Underweight $8
Dec-19-19Initiated Cantor Fitzgerald Overweight
Dec-18-19Initiated Cantor Fitzgerald Overweight
Nov-21-19Downgrade Morgan Stanley Equal-Weight → Underweight $17 → $6
Nov-20-19Resumed Guggenheim Neutral
May-03-19Upgrade Wedbush Neutral → Outperform $26
Apr-12-19Initiated Guggenheim Neutral
Feb-07-19Upgrade Citigroup Sell → Buy
Feb-07-19Downgrade Wedbush Outperform → Neutral
Feb-06-19Upgrade Raymond James Underperform → Mkt Perform
Feb-04-19Downgrade Citigroup Neutral → Sell $10
Dec-10-18Downgrade Raymond James Outperform → Underperform
Sep-10-18Resumed BTIG Research Buy $30
May-31-18Initiated Evercore ISI Outperform $33
Mar-05-18Initiated H.C. Wainwright Buy $38
Mar-31-17Initiated Raymond James Outperform $26
Mar-02-17Initiated Instinet Buy $41
Dec-20-16Initiated SunTrust Buy $30
Jul-09-20 06:43PM  
05:22PM  
Jun-27-20 09:28PM  
Jun-22-20 09:00AM  
Jun-16-20 07:30AM  
Jun-05-20 07:30AM  
Jun-03-20 04:05PM  
May-29-20 12:45PM  
May-28-20 07:30AM  
May-27-20 07:30AM  
03:50AM  
May-21-20 04:05PM  
May-18-20 07:06AM  
May-13-20 05:10PM  
May-12-20 08:40AM  
May-11-20 04:37PM  
11:14AM  
06:29AM  
May-08-20 08:10AM  
07:34AM  
May-06-20 03:01PM  
01:24PM  
May-05-20 06:45PM  
04:01PM  
08:36AM  
Apr-29-20 04:01PM  
Apr-28-20 04:01PM  
07:30AM  
Apr-27-20 12:05AM  
Apr-20-20 09:01AM  
Apr-17-20 08:54AM  
Mar-16-20 06:16PM  
Mar-10-20 01:50AM  
Mar-04-20 05:00PM  
Mar-02-20 08:45AM  
Feb-27-20 10:30AM  
07:30AM  
Feb-25-20 04:01PM  
Feb-24-20 02:48PM  
Feb-13-20 07:30AM  
Feb-10-20 07:30AM  
Jan-14-20 03:12PM  
Jan-13-20 07:30AM  
Jan-09-20 04:30PM  
Jan-06-20 05:14PM  
Dec-19-19 12:00PM  
Dec-11-19 10:00AM  
Dec-09-19 03:05PM  
Dec-07-19 08:35AM  
Nov-15-19 12:02PM  
Nov-13-19 04:55PM  
Nov-12-19 01:45PM  
12:45PM  
10:59AM  
10:29AM  
10:00AM  
09:36AM  
07:37AM  
03:29AM  
02:00AM  
Nov-11-19 03:35PM  
03:21PM  
01:45PM  
12:15PM  
12:00PM  
10:40AM  
09:41AM  
07:10AM  
Nov-10-19 12:00PM  
10:30AM  
Nov-09-19 07:35PM  
11:52AM  
Nov-08-19 08:15PM  
04:59PM  
03:00PM  
02:15PM  
01:00PM  
11:20AM  
10:40AM  
10:23AM  
09:50AM  
Nov-07-19 08:05PM  
05:30PM  
04:45PM  
04:39PM  
02:15PM  
01:30PM  
09:25AM  
Nov-06-19 07:50PM  
06:35PM  
06:00PM  
04:01PM  
03:30PM  
02:00PM  
01:30PM  
12:15PM  
10:39AM  
09:30AM  
09:12AM  
Nov-05-19 08:00PM  
MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets HER2-expressing tumors, such as various breast and gastroesophageal cancers. The company is also developing Flotetuzumab, a DART molecule that recognizes CD123 and CD3 for treating acute myeloid leukemia; MGA012, an investigational monoclonal antibody targeting PD-1; MGD013, a monoclonal antibody that targets the PD-1 and lymphocyte-activation gene 3; MGD019, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; and Enoblituzumab, a monoclonal antibody that targets B7-H3. In addition, the company is developing combination of MGD009 and MGA012; MGC018, an antibody drug conjugate, which targets solid tumors expressing B7-H3; and MGD014, a DART molecule that targets envelope protein of human immunodeficiency virus infected cells and T cells. It has strategic collaborations with Incyte Corporation; Zai Lab Limited; and I-Mab Biopharma. MacroGenics, Inc. was founded in 2000 and is headquartered in Rockville, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Risser Eric BlasiusSr VP & Chief Business OfficerJul 02Option Exercise1.513,1004,68147,568Jul 06 04:25 PM
Risser Eric BlasiusSr VP & Chief Business OfficerJul 02Sale30.003,10093,00044,468Jul 06 04:25 PM
Peters Jeffrey StuartGeneral CounselJul 02Sale30.002026,0600Jul 06 04:25 PM
Risser Eric BlasiusSr VP & Chief Business OfficerJun 24Option Exercise0.9450047044,968Jun 25 04:57 PM
Risser Eric BlasiusSr VP & Chief Business OfficerJun 24Sale28.4950014,24544,468Jun 25 04:57 PM
Risser Eric BlasiusSr VP & Chief Business OfficerMay 26Option Exercise0.9450047044,968May 27 04:43 PM
Risser Eric BlasiusSr VP & Chief Business OfficerMay 26Sale26.5950013,29544,468May 27 04:43 PM
Spitznagel ThomasSr VP, BPD & ManufacturingMay 20Option Exercise7.517,50056,3257,500May 21 07:44 PM
Spitznagel ThomasSr VP, BPD & ManufacturingMay 20Sale25.307,500189,7500May 21 07:44 PM
Risser Eric BlasiusSr VP & Chief Business OfficerMay 06Option Exercise1.478,03211,84352,500May 07 04:22 PM
Risser Eric BlasiusSr VP & Chief Business OfficerMay 06Sale20.958,032168,30044,468May 07 04:22 PM
Risser Eric BlasiusSr VP & Chief Business OfficerApr 16Option Exercise0.946,0005,64044,468Apr 17 04:11 PM
Risser Eric BlasiusSr VP & Chief Business OfficerMar 13Option Exercise0.946,0005,64038,468Mar 17 04:09 PM
Koenig ScottPresident and CEOMar 11Option Exercise0.94133,163125,173943,103Mar 13 04:15 PM
Karrels JamesSVP, CFO and SecretaryMar 06Option Exercise0.944,4734,205152,460Mar 09 04:39 PM
Risser Eric BlasiusSr VP & Chief Business OfficerFeb 20Option Exercise0.9450047032,968Feb 21 04:44 PM
Risser Eric BlasiusSr VP & Chief Business OfficerFeb 20Sale10.845005,42032,468Feb 21 04:44 PM
Risser Eric BlasiusSr VP & Chief Business OfficerFeb 05Option Exercise0.9462358633,091Feb 06 04:41 PM
Risser Eric BlasiusSr VP & Chief Business OfficerFeb 05Sale10.006236,23032,468Feb 06 04:41 PM
Risser Eric BlasiusSr VP & Chief Business OfficerFeb 04Option Exercise0.94302832,498Feb 06 04:41 PM
Risser Eric BlasiusSr VP & Chief Business OfficerFeb 04Sale10.003030032,468Feb 06 04:41 PM
Karrels JamesSVP, CFO and SecretaryJan 30Option Exercise0.9412,50011,750147,987Jan 31 04:45 PM
Risser Eric BlasiusSr VP & Chief Business OfficerSep 27Option Exercise0.941,6621,56232,468Oct 03 04:33 PM